Amy Weise

1.9k total citations
69 papers, 946 citations indexed

About

Amy Weise is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Amy Weise has authored 69 papers receiving a total of 946 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Amy Weise's work include Advanced Breast Cancer Therapies (17 papers), Cancer Immunotherapy and Biomarkers (17 papers) and HER2/EGFR in Cancer Research (11 papers). Amy Weise is often cited by papers focused on Advanced Breast Cancer Therapies (17 papers), Cancer Immunotherapy and Biomarkers (17 papers) and HER2/EGFR in Cancer Research (11 papers). Amy Weise collaborates with scholars based in United States, Spain and United Kingdom. Amy Weise's co-authors include Patricia LoRusso, Wei‐Zen Wei, Anthony F. Shields, Ulka N. Vaishampayan, David S. Hong, Olga Radkevich-Brown, Lawrence E. Flaherty, Maureen G. Conlan, Rebecca G. Bagley and Gary K. Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Amy Weise

67 papers receiving 926 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Weise United States	19	530	438	259	191	102	69	946
Rumey C. Ishizawar United States	8	436 0.8×	600 1.4×	170 0.7×	94 0.5×	111 1.1×	13	1.1k
Meredith McKean United States	16	591 1.1×	483 1.1×	137 0.5×	238 1.2×	66 0.6×	118	961
Takafumi Koyama Japan	19	447 0.8×	293 0.7×	168 0.6×	136 0.7×	144 1.4×	87	871
Teresa Di Desidero Italy	24	542 1.0×	421 1.0×	253 1.0×	74 0.4×	200 2.0×	52	1.1k
Nobuya Yamada Japan	18	579 1.1×	379 0.9×	148 0.6×	109 0.6×	292 2.9×	74	1.1k
David James VanderWeele United States	15	300 0.6×	485 1.1×	355 1.4×	108 0.6×	262 2.6×	57	1.0k
G Mariani Italy	14	561 1.1×	378 0.9×	275 1.1×	230 1.2×	117 1.1×	33	917
Melissa M. Johnson United States	15	232 0.4×	344 0.8×	103 0.4×	175 0.9×	121 1.2×	36	756
Theresa A. Mays United States	10	477 0.9×	773 1.8×	218 0.8×	126 0.7×	137 1.3×	15	1.2k
Philip Bonomi United States	15	593 1.1×	592 1.4×	403 1.6×	112 0.6×	120 1.2×	37	1.2k

Countries citing papers authored by Amy Weise

Since Specialization

Citations

This map shows the geographic impact of Amy Weise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Weise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Weise more than expected).

Fields of papers citing papers by Amy Weise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Weise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Weise. The network helps show where Amy Weise may publish in the future.

Co-authorship network of co-authors of Amy Weise

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Weise. A scholar is included among the top collaborators of Amy Weise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Weise. Amy Weise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamilton, Erika, Hyo S. Han, Kevin Kalinsky, et al.. (2025). Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le), a novel B7-H4-directed dolasynthen antibody-drug conjugate.. Journal of Clinical Oncology. 43(16_suppl). 3009–3009. 1 indexed citations

Piha‐Paul, Sarina A., Macarena I. de la Fuente, Fábio M. Iwamoto, et al.. (2024). Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3107–3107. 3 indexed citations

Hamilton, Erika, Alexander I. Spira, Sylvia Adams, et al.. (2023). XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250). Gynecologic Oncology. 176. S158–S158.

Hamilton, Erika, Arvind Chaudhry, Alexander I. Spira, et al.. (2023). XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.. Journal of Clinical Oncology. 41(16_suppl). TPS3154–TPS3154. 6 indexed citations

Bardia, Aditya, Virginia Kaklamani, Sharon Wilks, et al.. (2021). Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. Journal of Clinical Oncology. 39(12). 1360–1370. 67 indexed citations

Tsimberidou, Apostolia M., Dejan Juric, Claire F. Verschraegen, et al.. (2021). Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. Journal of Hematology & Oncology. 14(1). 127–127. 20 indexed citations

Heath, Elisabeth I., et al.. (2021). Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 40(2). 300–307. 8 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Afshin Dowlati, et al.. (2020). A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. British Journal of Cancer. 124(4). 744–753. 83 indexed citations

Goff, Laura W., Nilofer S. Azad, Stacey Stein, et al.. (2018). Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Investigational New Drugs. 37(2). 315–322. 13 indexed citations

10.

Tsimberidou, Apostolia M., Claire F. Verschraegen, Amy Weise, et al.. (2018). Precision oncology: Results of a phase I study of M2698, a p70S6K/AKT targeted agent in patients with advanced cancer and tumor PI3K/AKT/mTOR (PAM) pathway abnormalities.. Journal of Clinical Oncology. 36(15_suppl). 2584–2584. 1 indexed citations

11.

Naing, Aung, Sanjay Goel, Brendan D. Curti, et al.. (2016). A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors. Annals of Oncology. 27. vi367–vi367. 1 indexed citations

12.

Rosen, Lee S., Patricia LoRusso, Wen Wee, et al.. (2016). A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs. 34(5). 604–613. 62 indexed citations

13.

Gibson, Heather M., Jesse Veenstra, Richard Jones, et al.. (2015). Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunology Research. 3(7). 777–786. 11 indexed citations

14.

Hu‐Lieskovan, Siwen, Amita Patnaik, Peter D. Eisenberg, et al.. (2015). Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. Annals of Oncology. 26. viii5–viii5. 4 indexed citations

15.

Weise, Amy & Lawrence E. Flaherty. (2014). New Options for the Adjuvant Treatment of Cutaneous Melanoma?. Current Oncology Reports. 16(11). 409–409. 10 indexed citations

16.

Gadgeel, Shirish M. & Amy Weise. (2014). New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer. SHILAP Revista de lepidopterología. 5. 35–35. 1 indexed citations

17.

Jacob, Jennifer B., Elena Quaglino, Olga Radkevich-Brown, et al.. (2010). Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity. Cancer Research. 70(1). 119–128. 35 indexed citations

18.

Weise, Amy, Josie L. Falany, Charles N. Falany, et al.. (2009). Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. Breast Cancer Research and Treatment. 120(1). 35–45. 33 indexed citations

19.

Radkevich-Brown, Olga, et al.. (2008). Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunology Immunotherapy. 58(5). 759–767. 16 indexed citations

20.

Fulton, Amy M., Frederick W. Miller, Amy Weise, & Wei‐Zen Wei. (2007). Prospects of Controlling Breast Cancer Metastasis by Immune Intervention. Breast Disease. 26(1). 115–127. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact